Treace Medical Concepts, Inc. (TMCI) announced that it has successfully completed its first surgical cases using the SuperBite™ Compression Screw System, a headless, self‑drilling screw that features a variable thread pitch and countersinking capability. The system is available in diameters ranging from 2.5 mm to 7.0 mm and is designed for both minimally invasive and open foot and ankle procedures.
Dr. Anne Holly Johnson of the Hospital for Special Surgery in New York performed the first cases and said, "My first cases with the SuperBite™ screws were very successful. I was impressed with the streamlined insertion and great compression. Compression screws are the most common fixation used in foot and ankle surgery, and I plan to use the SuperBite™ screws in many different fusion and osteotomy applications."
The company plans to launch the product for full commercialization in the third quarter of 2026. The SuperBite™ system’s advanced compression technology is expected to broaden Treace’s product line and provide surgeons with a versatile tool for a wide range of foot and ankle procedures.
Treace’s CEO John T. Treace said, "The launch of SuperBite™ represents an important milestone in the expansion of our market‑leading bunion & midfoot technology portfolio. SuperBite™ allows our direct sales team to more fully service our 3,300+ surgeon customers technology needs, not only in the procedures they perform with Treace today, but also a significant volume of incremental procedures throughout the foot and ankle where compression screws are utilized." He added, "We believe SuperBite™ screws will expand our addressable market, accelerate our case volumes, and grow our customer share of wallet, all while further advancing our position as a 1‑stop‑shop for our customers."
The launch is part of a broader strategy to increase case volumes and wallet share. Treace’s 3,300+ surgeon customer base and direct‑sales model position the company to capture a larger share of the foot and ankle market. The company estimates that the combined impact of SuperBite™ and the upcoming SpeedXM™ Midfoot Fusion System will add roughly $300 million to its addressable market.
While the product launch is a positive development, Treace’s financial guidance for 2026 reflects ongoing headwinds. In Q4 2025 the company reported a net loss of $9.4 million and an adjusted EBITDA of $6.2 million. Full‑year 2025 results showed a net loss of $59.0 million and an adjusted EBITDA loss of $3.9 million, compared with a $11.0 million loss in 2024. For 2026, the company has guided revenue of $200 million to $212 million—potentially a 6 % to 0 % decline from 2025—and an adjusted EBITDA loss of $4.0 million to $6.0 million. The SuperBite™ launch is expected to help reverse these trends by driving future case volumes and revenue growth.
The announcement marks a significant milestone in Treace’s product development pipeline and signals the company’s intent to strengthen its competitive position in the foot and ankle market, even as it navigates current financial challenges.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.